Section 5 of 6
Economic information and modeling report
28 evidence topics · 23 sources
Modeling overview
Summary: published economic evidence for comparators
No cost-effectiveness analysis or budget impact model of palazestrant has been published, and no price exists. Published evaluations address the comparators. For elacestrant, a U.S. third-party payer partitioned survival model over 10 years using EMERALD data estimated incremental cost-effectiveness ratios of $8,672,360 per QALY gained compared with standard of care in the overall population and $2,900,560 per QALY gained compared with fulvestrant in the ESR1-mutation subgroup, with a 0% probability of cost-effectiveness at $150,000 per QALY gained. NICE recommends elacestrant for ESR1-mutated disease that progressed after at least 12 months of endocrine treatment plus a CDK4/6 inhibitor, under a commercial arrangement; the committee judged an acceptable ICER to be towards the upper end of £20,000 to £30,000 per QALY gained, the exact estimates are confidential, and the company model assumed £300 per digital polymerase chain reaction ESR1 test and a 50% ESR1-mutation prevalence, or £600 for each case identified for treatment. NICE states that it is “unable to make a recommendation about the use in the NHS of imlunestrant” because the company “does not intend to make an evidence submission for the evaluation”. For capivasertib plus fulvestrant compared with fulvestrant alone, U.S. analyses estimated $128,283.61 per QALY (0.62 incremental QALYs at an incremental cost of $79,117.66; U.S. health care perspective, 10-year horizon, $100,000 per QALY threshold), $280,854 per QALY (lifetime horizon, with a price reduction of nearly 70%, to $7000 per cycle, needed for cost-effectiveness), $636,455 per QALY gained in the PIK3CA/AKT1/PTEN-altered subgroup over 5 years in 2025 U.S. dollars (requiring a reduction from $28,332 to $5,598 per 4 weeks), and $709,647 per QALY in a fourth analysis. The CADTH (Canada) reimbursement review estimated $221,165 per QALY gained compared with endocrine monotherapy, stated that a price reduction of 85% would be required to reach $50,000 per QALY gained, and estimated a 3-year budget impact to public drug plans of $81,103,794, rising to $135,910,918 with 100% testing uptake. A U.S. budget impact analysis of second-line capivasertib in 2023 US dollars estimated 113, 114, and 115 eligible individuals per 1-million-member population in years 1 to 3, $31,939,838 in net costs over 3 years, and $0.88 per member per month. Alpelisib plus fulvestrant had an ICER of $340,153.30 per QALY gained from a U.S. payer perspective. In a 5-year analysis of patient-level data, CDK4/6 inhibitor use in the first line compared with the second line had healthcare costs of €61,821 and €39,057 and an ICER of €423,408 per QALY gained. No Institute for Clinical and Economic Review assessment of therapies for this population was identified.
U.S. payer cost-effectiveness analysis of elacestrant versus standard endocrine therapy in the second or third line
“The 3 health states partitioned survival model (PSM) was conducted from the perspective of the US third-party payers. The time horizon for the model lasted 10 years. Effectiveness and safety data were derived from the EMERALD trial (NCT03778931).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ELA led to an incremental cost-effectiveness ratio (ICER) of $8,672,360/quality-adjusted life year (QALY) gained compared with SOC in the overall population and $2,900,560/QALY gained compared with fulvestrant (FUL) in the ESR1(estrogen receptor 1) mutation subgroup.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The two ICERs of ELA were significantly higher than the willingness-to-pay (WTP) threshold values of $150,000/QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both overall population and subgroup, the probability of ELA being cost-effective vs. SOC or FUL at thresholds of $150,000 per QALY gained was 0%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ELA was not cost-effective for the second-/third-line treatment of patients with ER+/HER2–A/MBC compared with SOC in the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drug acquisition costs in the U.S. elacestrant model
“As we adopted the perspective of American payers, we only consider direct healthcare costs, including drug acquisition costs, administration and medical fees for each state, end-of-life care costs, and costs associated with MAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The drug unit costs were obtained from the Centers for Medicare & Medicaid Services and AWP&AAC Medicaid, while all other costs were derived from published economic articles on similar drugs, and the cost per cycle was calculated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the high cost ($22511.06 for 30 tablets, 345mg per tablet)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drug cost parameters in the U.S. elacestrant model, US dollars
NICE recommendation for elacestrant in ESR1-mutated disease
NICE committee cost-effectiveness estimates and ESR1-mutation testing cost for elacestrant
CADTH reimbursement recommendation for capivasertib plus fulvestrant: cost-effectiveness
CADTH reimbursement recommendation for capivasertib plus fulvestrant: budget impact
U.S. health care perspective cost-effectiveness analysis of capivasertib plus fulvestrant (CAPItello-291 overall population)
“This model adopted a willingness-to-pay (WTP) threshold of $100,000 per quality-adjusted life-year (QALY) from a US health care perspective. A 10-year lifetime horizon with a monthly cycle length was used with a 3% discount on costs and utilities derived from previously published resources.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the base model, capivasertib plus fulvestrant treatment was expected to generate an incremental 0.62 QALYs at an incremental cost of $79,117.66, which resulted in an incremental cost-effectiveness ratios of $128,283.61/QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The findings from this study suggest that adding capivasertib to fulvestrant treatment is not cost-effective when compared with fulvestrant alone, from the perspective of the US health care system.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The drug costs per unit were calculated using the 2023 average sale price data provided by the Centers for Medicare & Medicaid Services.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. payer cost-effectiveness analysis of capivasertib plus fulvestrant (partitioned survival model)
“The base-case analysis estimated the ICUR for capivasertib plus fulvestrant versus fulvestrant alone to be $709,647 per quality-adjusted life-year (QALY) in the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OWSA revealed that the results were sensitive to hazard ratio of OS and the cost of capivasertib. PSA demonstrated that capivasertib plus fulvestrant exhibited a 0% probability of cost-effectiveness in the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
U.S. payer cost-effectiveness analysis of capivasertib plus fulvestrant (lifetime horizon)
“Analyses were conducted from a US payer perspective over a lifetime horizon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The addition of capivasertib to fulvestrant for all patients was associated with $410,765 higher costs and 1.46 additional quality adjusted life years (QALYs) compared with fulvestrant alone, resulting in an incremental cost effectiveness ratio of $280,854/QALY.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The price of capivasertib will need to be reduced by nearly 70% (to $7000 per cycle) for it to become cost effective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. payer cost-effectiveness analysis of capivasertib plus fulvestrant (PIK3CA/AKT1/PTEN-altered subgroup)
“Capivasertib cost was based on wholesale acquisition cost. Costs were presented in 2025 U.S. dollars.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Capivasertib plus fulvestrant yielded more QALYs (1.89 vs. 1.29) and life years (3.31 vs. 2.49) but higher costs ($539,625 vs. $158,679) than fulvestrant alone, resulting in ICERs of $636,455/QALY gained and $459,358/evLYG over a 5-year time horizon.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The cost of capivasertib ($28,332/4 weeks) had the greatest impact and would need to be reduced to $5,598/4 weeks to achieve cost-effectiveness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. payer cost-effectiveness analysis of alpelisib plus fulvestrant (PIK3CA-mutated disease)
“The QALY increased by 0.28 with alpelisib plus fulvestrant with an additional cost of $94,345.87 compared with placebo plus fulvestrant, leading to an incremental cost-effectiveness ratio (ICER) of $340,153.30/QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At current drug prices, alpelisib plus fulvestrant is not cost effective for patients with PIK3CA-mutated, HR+/HER2- ABC from a US payer perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of CDK4/6 inhibitor use in first versus second line (SONIA)
“We estimated the cost-effectiveness of CDK4/6i use in first- versus second-line over 5 years using patient-level data.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Healthcare costs were higher among patients receiving CDK4/6i in first- versus second-line (€61,821 [SE 1423] versus €39,057 [SE 1513]; difference €22,764, 95 % CI €18,815 to €26,713).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The ICER was €423,408 per QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Delaying CDK4/6i treatment to second-line leads to large cost savings while achieving the same patient health outcomes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. budget impact analysis of capivasertib as second-line therapy
“We estimated the change in total costs from adding capivasertib to the treatment mix over 3 years. The size of the target population was estimated using data on incidence and prevalence for breast cancer, PIK3CA/AKT1/PTEN alterations, and risk of failure to first-line treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Costs were measured in 2023 US dollars.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In a 1-million-member population, 113, 114, and 115 individuals would be eligible for capivasertib treatment in years 1, 2, and 3, respectively. Adding capivasertib to the second-line setting would add $31,939,838 in net costs over 3 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Specifically, drug costs would increase by $34,251,781 but would be offset by savings of $323,632 in adverse event costs and of $1,988,311 in follow-up costs. These net costs amount to $0.88 per-member-per-month.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
ICER review of therapies for ER-positive HER2-negative advanced breast cancer
No evidence found.
Eligible population input: incident invasive breast cancer in the United States, 2026
Eligible population input: stage distribution at diagnosis and prevalence of female breast cancer
Eligible population input: share of female breast cancer that is HR-positive HER2-negative
Eligible population input: number of women living with metastatic breast cancer in the United States
“By January 1, 2025, the following numbers of individuals are projected to be living with metastatic cancer in the United States: breast, 169 347” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Cancer type | New metastatic cases, 2018, de novo (observed) | New metastatic cases, 2018, de novo and recurrence (estimated) | Living with metastatic disease on January 1, 2018, de novo (observed) | Living with metastatic disease on January 1, 2018, de novo and recurrence (estimated) |
|---|---|---|---|---|
| “Breast (female)”View highlighted excerpt for this quote | “15 800”View highlighted excerpt for this quote | “46 666”View highlighted excerpt for this quote | “54 117”View highlighted excerpt for this quote | “140 230”View highlighted excerpt for this quote |
Eligible population input: second-line treatment after first-line CDK4/6 inhibitor therapy in U.S. practice
“A total of 1210 patients with MBC received a CDK4/6i with ET as their documented first-line systemic therapy from years 2015-2020” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eight hundred thirty-nine patients received a documented second-line systemic therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cytotoxic chemotherapy was the most common second-line therapy, followed by endocrine monotherapy, administered to 249 (29.7%) and 104 (12.4%) of patients, respectively. Fulvestrant was the most commonly prescribed endocrine monotherapy (70 patients, 8.3%). Other targeted therapies used were everolimus (99 patients, 11.7%), alpelisib (16 patients, 1.9%) and a PARP inhibitor (4 patients, 0.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three hundred two (36.0%) of patients continued a CDK4/6i.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment duration input: real-world progression-free survival of second-line regimens after first-line CDK4/6 inhibitor therapy
“Twenty records (9 full-text articles and 11 conference abstracts) encompassing 18 unique studies met the eligibility criteria and reported outcomes for second-line (2 L) treatments after 1 L CDK4/6i; no studies reported disaggregated outcomes in the third-line setting or beyond.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligible population input: ESR1-mutation prevalence by line of therapy
“Evaluating specimens collected at or near the time of therapy initiation, the prevalence of ESR1mut in TBx collected within 60 days before or after the initiation of 1st, 2nd, and 3rd lines of therapy was 8.1% (n = 175/2,154), 27.1% (n = 73/269), and 33.3% (n = 72/216), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of ESR1mut in LBx collected proximal to initiation of 1st, 2nd, and 3rd lines of therapy was 10.4% (n = 30/288), 37.6% (n = 74/197), and 38.7% (n = 46/119), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company market-size statements in the annual report
Company estimate of the U.S. second- and third-line population and market
Comparator price: imlunestrant wholesale acquisition cost
| Generic name | Strength | Dosage form | Pack size | NDC | Wholesale acquisition cost |
|---|---|---|---|---|---|
| “imlunestrant” | “200 MG” | “Tablet” | “28” | “0002-1717-28” | “$11,250.00” |
| “imlunestrant” | “200 MG” | “Tablet” | “56” | “0002-1717-56” | “$22,500.00” |
Comparator price: elacestrant wholesale acquisition cost at launch
| Name of prescription drug | Strength | Pack size | WAC (as of date of commercial availability) | Date of commercial availability |
|---|---|---|---|---|
| “Orserdu (elacestrant)” | “86 mg” | “30 tablets” | “$7,123.00” | “2/3/2023” |
| “Orserdu (elacestrant)” | “345 mg” | “30 tablets” | “$21,369.00” | “2/3/2023” |
Comparator price: fulvestrant cost per cycle in a U.S. model based on CMS average sales price
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.